Stoke Therapeutics
STOK
126 hedge funds and large institutions have $422M invested in Stoke Therapeutics in 2025 Q1 according to their latest regulatory filings, with 23 funds opening new positions, 45 increasing their positions, 30 reducing their positions, and 27 closing their positions.
50% more repeat investments, than reductions
Existing positions increased: 45 | Existing positions reduced: 30
7.59% more ownership
Funds ownership: 109.61% → 117.2% (+7.6%)
0% more funds holding in top 10
Funds holding in top 10: 3 → 3 (0)
3% less funds holding
Funds holding: 130 → 126 (-4)
15% less first-time investments, than exits
New positions opened: 23 | Existing positions closed: 27
34% less capital invested
Capital invested by funds: $640M → $422M (-$219M)
94% less call options, than puts
Call options by funds: $60K | Put options by funds: $973K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$22.2M |
| 2 |
Marshall Wace
London,
United Kingdom
|
+$11M |
| 3 |
Bank of America
Charlotte,
North Carolina
|
+$4.88M |
| 4 |
CC
Checkpoint Capital
San Francisco,
California
|
+$3.97M |
| 5 |
EAM
Erste Asset Management
Vienna,
Austria
|
+$3.69M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Assenagon Asset Management
Senningerberg,
Luxembourg
|
-$3.65M |
| 2 |
Norges Bank
Oslo,
Norway
|
-$3.47M |
| 3 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$3.03M |
| 4 |
Squarepoint
New York
|
-$1.33M |
| 5 |
EAM
Exome Asset Management
New York
|
-$1.25M |
STOK Hedge Fund Activity: Q1 2025 in Review
126 of the 7,458 institutional investors tracked by Wall St. Rank reported a position in Stoke Therapeutics (STOK) for Q1 2025, worth a combined $422M — down 34% from $640M a quarter earlier.
Sellers outnumbered buyers: 27 funds closed out of STOK and 23 opened new positions — a net loss of 4 holders — while 30 trimmed existing stakes and 45 added.
The largest buyer was Fidelity Investments, adding an estimated $22.2M. The largest seller was Assenagon Asset Management, cutting an estimated $3.65M.
- 126 institutional investors held Stoke Therapeutics (STOK) as of Q1 2025, down from 130 in Q4 2024.
- Funds reported $422M of Stoke Therapeutics stock for Q1 2025, down 34% quarter-over-quarter.
- 23 funds opened new Stoke Therapeutics positions in Q1 2025 and 27 closed out, a net change of -4 holders.
- The largest Stoke Therapeutics buyer in Q1 2025 was Fidelity Investments, an estimated $22.2M added.
- The largest Stoke Therapeutics seller in Q1 2025 was Assenagon Asset Management, an estimated $3.65M sold.
Based on aggregated 13F filings for Q1 2025.